MedTrace Logo

Chemoablation for Low-Grade Bladder Cancer

NCT07019220 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2025-06-13

No results posted yet for this study

Summary

The goal of this single arm, prospective, open-label, investigator-initiated Phase 2 clinical trial is to evaluate the efficacy of intravesical chemoablation in patients with low grade bladder cancer.

Conditions

  • Bladder (Urothelial, Transitional Cell) Cancer

Interventions

DRUG

Gemcitabine

Intravesical installation

Sponsors & Collaborators

  • Ekaterina Laukhtina

    lead OTHER

Principal Investigators

  • Shahrokh F. Shariat Prof. Dr., Professor · Department of Urology, Medical University of Viernna

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-27
Primary Completion
2027-11-30
Completion
2027-11-30

Countries

  • Austria

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07019220 on ClinicalTrials.gov